Keyrus and Innovation Sprint partnership
Innovation Sprint and Keyrus Life Science join forces to combine Clinical Research expertise with “Healthentia™ ePRO” capabilities to reach the next level in patient engagement for clinical research.

 

The latest partnership between Innovation Sprint and Keyrus Life Science will combine both advanced clinical research trial strategy with the best-in-class ePRO technology, Healthentia, to facilitate patient monitoring, bringing more value to Pharma, Biotechs, and Medtechs in achieving successful development projects.

Innovation Sprint, a digital MedTech startup from Belgium, provides solutions to life sciences and healthcare through its innovative solution Healthentia, which captures Real World Data (RWD) from patients and supports Decentralized Clinical Trials (DCT).

Keyrus Life Science, operating across Europe and North America, connects CRO expertise, life data science, and digital enablement to fully leverage both clinical research ecosystems and real-world evidence to help life science organizations shape and conduct their clinical research strategies.

The collaboration with Keyrus Life Science opens new horizons for Innovation Sprint and its product Healthentia, as both companies are sharing a common vision about the evolution of life sciences and the convergence with healthcare applications. “Decentralized Clinical Trials are gaining more traction in Europe and North America and our challenge is to facilitate the clinical trial process with simplicity and efficiency for CROs, while increasing patient engagement and compliance” said Dr. Sofoklis Kyriazakos, CEO of Innovation Sprint. By leveraging best-of-breed cloud-computing, IoT, AI, and virtual coaching technologies, Healthentia is elevating ePRO capabilities to new horizons.

Keyrus Life Science is constantly pursuing the best and most innovative technologies to empower clinical research by leveraging both data and digital capabilities. “We are today honored to sign this strategic partnership with Innovation Sprint, that will allow to deliver to the Life Science sector a new alternative to go further in patient centricity for their more demanding clinical research programs” highlighted Michaël Attlan, VP Life Science at Keyrus. The strong commitment of Keyrus Life Science in supporting R&D programs finds with this partnership a new reach to achieve improved patient outcomes and clinical research efficiency.


About Us:

Innovation Sprint:
Innovation Sprint is a digital MedTech company that provides solutions to life sciences and healthcare through its product Healthentia. Healthentia is a Software as Medical Device (SaMD) that monitors, detects, offers virtual coaching services, and generates automatic alerts regarding events, based on Real World Data gathered from patients using it for Remote Patient Monitoring (RPM), Decentralized Clinical Trials (DCT), or Digital Therapeutics (DTx). As the name indicates, the company has embraced innovation from its start, to provide a best-in-class solution utilizing edge technologies. In 2022, Innovation Sprint won the EC prize “Innovation Radar” as Health Disruptor.

For more information, visit https://innovationsprint.eu , https://healthentia.com

 

Keyrus Life Science:
With more than 25 years of experience, Keyrus Life Science makes data matter to address the biggest clinical challenges for clients around the globe to enable long-term success. As part of the Keyrus Group, an international data and digital company, we connect CRO expertise, life data science and digital enablement to improve clinical trial efficiency and agility, to the utmost benefit of society and human health. As an innovation-centric company by design, we anticipate the future health needs in clinical research and uncover new solutions and technologies to develop faster the cures of tomorrow. With the help of the most advanced partners in the clinical research domain, we provide full services to optimize patient recruitment and engagement, leverage insights from data, and to unlock new horizons for personalized therapeutic approaches.

For more information, visit https://keyruslifescience.com